



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/456005/2013

European Medicines Agency decision

P/0203/2013

of 2 September 2013

on the granting of a product specific waiver for pomalidomide (EMA-001457-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0203/2013

of 2 September 2013

on the granting of a product specific waiver for pomalidomide (EMA-001457-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Celgene Europe Ltd on 11 April 2013 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 July 2013 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for pomalidomide, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, UB11 1DB – Uxbridge, United Kingdom.

Done at London, 2 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/276259/2013

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001457-PIP01-13

Scope of the application

Active substance(s):

Pomalidomide

Condition(s):

Treatment of post-essential thrombocythaemia myelofibrosis

Treatment of post-polycythaemia vera myelofibrosis

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Celgene Europe Ltd

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Celgene Europe Ltd submitted to the European Medicines Agency on 11 April 2013 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 22 May 2013.



Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and all the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 July 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition: treatment of post-essential thrombocythaemia myelofibrosis

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for hard capsule, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition: treatment of post-polycythaemia vera myelofibrosis

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for hard capsule, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).